Can Pfizer Beat Moderna in mRNA Vaccines?
Before the pandemic, most of us probably didn't spend a lot of time thinking about messenger RNA (mRNA). But Moderna (NASDAQ: MRNA) changed that. The biotech company brought mRNA to center stage when it began developing its coronavirus vaccine. The vaccine uses mRNA to instruct the body's cells to produce a specific protein. From here, our immune system creates antibodies necessary to block infection.
Moderna didn't develop this technology overnight, though. The company has been working on it for more than a decade. In fact, it has mRNA candidates in the pipeline for a variety of therapeutic areas. Its coronavirus vaccine rival Pfizer (NYSE: PFE) is a newcomer to mRNA. It got into the business through partnerships with Germany's BioNTech. But Pfizer has big mRNA plans. Now the question is: Should Moderna be worried?
Image source: Getty Images.
Source Fool.com
